img

Global Oligonucleotide Therapy Market Insights, Forecast to 2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Oligonucleotide Therapy Market Insights, Forecast to 2034

Many pharmaceutical companies were conducting research on oligonucleotide therapy, which employs chemically synthesized nucleotide-like small molecule drugs with potential specificity similar to that of therapeutic antibodies.
Although several types of oligonucleotide therapies exist, five of them are compared here, including the ones targeting nucleic acids (such as mRNA) or proteins, as well as others intended for stimulation of the immune system. DDS is generally used with oligonucleotide therapy, as it is difficult for these molecules to penetrate cell membrane when administered on their own.
Market Analysis and InsightsGlobal Oligonucleotide Therapy Market
The global Oligonucleotide Therapy market is projected to grow from US$ 3831.8 million in 2024 to US$ 4746.7 million by 2034, at a Compound Annual Growth Rate (CAGR) of 3.6% during the forecast period.
Biogen is the industry's biggest player, with more than 76 percent of 2018 revenue, followed by Sarepta Therapeutics and Jazz Pharmaceuticals, with 13.35 percent and 6.63 percent, respectively. North America and Europe are the most important regions, accounting for more than 80 percent of the combined income.
Report Includes
This report presents an overview of global market for Oligonucleotide Therapy market size. Analyses of the global market trends, with historic market revenue data for 2018 - 2022, estimates for 2024, and projections of CAGR through 2034.
This report researches the key producers of Oligonucleotide Therapy, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Oligonucleotide Therapy, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Oligonucleotide Therapy revenue, market share and industry ranking of main companies, data from 2018 to 2024. Identification of the major stakeholders in the global Oligonucleotide Therapy market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2018 to 2034. Evaluation and forecast the market size for Oligonucleotide Therapy revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Alnylam Pharmaceuticals Inc., Biogen, Dynavax Technologies Corp., Merck and Co., Miragen Therapeuutics Inc., Sarepta Therapeutics Inc., GlaxoSmithKline, Pfizer and Gilead Sciences, etc.



By Company


Alnylam Pharmaceuticals Inc.
Biogen
Dynavax Technologies Corp.
Merck and Co.
Miragen Therapeuutics Inc.
Sarepta Therapeutics Inc.
GlaxoSmithKline
Pfizer
Gilead Sciences
Segment by Type
Antisense Oligonucleotide
Aptamer
Others

Segment by Application


Infectious Diseases
Oncology
Neurodegenerative Disorders
Cardiovascular Diseases
Kidney Diseases
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East, Africa, and Latin America
Turkey
Saudi Arabia
UAE
Rest of MEA

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Revenue of Oligonucleotide Therapy in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3Detailed analysis of Oligonucleotide Therapy companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America by type, by application and by country, revenue for each segment.
Chapter 7Europe by type, by application and by country, revenue for each segment.
Chapter 8China by type and by application revenue for each segment.
Chapter 9Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by type, by application and by country, revenue for each segment.
Chapter 11Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Oligonucleotide Therapy revenue, gross margin, and recent development, etc.
Chapter 12Analyst's Viewpoints/Conclusions

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Oligonucleotide Therapy Market Size Growth Rate by Type, 2018 VS 2022 VS 2034
1.2.2 Antisense Oligonucleotide
1.2.3 Aptamer
1.2.4 Others
1.3 Market by Application
1.3.1 Global Oligonucleotide Therapy Market Size Growth Rate by Application, 2018 VS 2022 VS 2034
1.3.2 Infectious Diseases
1.3.3 Oncology
1.3.4 Neurodegenerative Disorders
1.3.5 Cardiovascular Diseases
1.3.6 Kidney Diseases
1.3.7 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Oligonucleotide Therapy Market Perspective (2018-2034)
2.2 Global Oligonucleotide Therapy Growth Trends by Region
2.2.1 Oligonucleotide Therapy Market Size by Region: 2018 VS 2022 VS 2034
2.2.2 Oligonucleotide Therapy Historic Market Size by Region (2018-2024)
2.2.3 Oligonucleotide Therapy Forecasted Market Size by Region (2024-2034)
2.3 Oligonucleotide Therapy Market Dynamics
2.3.1 Oligonucleotide Therapy Industry Trends
2.3.2 Oligonucleotide Therapy Market Drivers
2.3.3 Oligonucleotide Therapy Market Challenges
2.3.4 Oligonucleotide Therapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Oligonucleotide Therapy by Players
3.1.1 Global Oligonucleotide Therapy Revenue by Players (2018-2024)
3.1.2 Global Oligonucleotide Therapy Revenue Market Share by Players (2018-2024)
3.2 Global Oligonucleotide Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Oligonucleotide Therapy, Ranking by Revenue, 2021 VS 2022 VS 2024
3.4 Global Oligonucleotide Therapy Market Concentration Ratio
3.4.1 Global Oligonucleotide Therapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Oligonucleotide Therapy Revenue in 2022
3.5 Global Key Players of Oligonucleotide Therapy Head office and Area Served
3.6 Global Key Players of Oligonucleotide Therapy, Product and Application
3.7 Global Key Players of Oligonucleotide Therapy, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Oligonucleotide Therapy Breakdown Data by Type
4.1 Global Oligonucleotide Therapy Historic Market Size by Type (2018-2024)
4.2 Global Oligonucleotide Therapy Forecasted Market Size by Type (2024-2034)
5 Oligonucleotide Therapy Breakdown Data by Application
5.1 Global Oligonucleotide Therapy Historic Market Size by Application (2018-2024)
5.2 Global Oligonucleotide Therapy Forecasted Market Size by Application (2024-2034)
6 North America
6.1 North America Oligonucleotide Therapy Market Size (2018-2034)
6.2 North America Oligonucleotide Therapy Market Size by Type
6.2.1 North America Oligonucleotide Therapy Market Size by Type (2018-2024)
6.2.2 North America Oligonucleotide Therapy Market Size by Type (2024-2034)
6.2.3 North America Oligonucleotide Therapy Market Share by Type (2018-2034)
6.3 North America Oligonucleotide Therapy Market Size by Application
6.3.1 North America Oligonucleotide Therapy Market Size by Application (2018-2024)
6.3.2 North America Oligonucleotide Therapy Market Size by Application (2024-2034)
6.3.3 North America Oligonucleotide Therapy Market Share by Application (2018-2034)
6.4 North America Oligonucleotide Therapy Market Size by Country
6.4.1 North America Oligonucleotide Therapy Market Size by Country: 2018 VS 2022 VS 2034
6.4.2 North America Oligonucleotide Therapy Market Size by Country (2018-2024)
6.4.3 North America Oligonucleotide Therapy Market Size by Country (2024-2034)
6.4.4 United States
6.4.5 Canada
7 Europe
7.1 Europe Oligonucleotide Therapy Market Size (2018-2034)
7.2 Europe Oligonucleotide Therapy Market Size by Type
7.2.1 Europe Oligonucleotide Therapy Market Size by Type (2018-2024)
7.2.2 Europe Oligonucleotide Therapy Market Size by Type (2024-2034)
7.2.3 Europe Oligonucleotide Therapy Market Share by Type (2018-2034)
7.3 Europe Oligonucleotide Therapy Market Size by Application
7.3.1 Europe Oligonucleotide Therapy Market Size by Application (2018-2024)
7.3.2 Europe Oligonucleotide Therapy Market Size by Application (2024-2034)
7.3.3 Europe Oligonucleotide Therapy Market Share by Application (2018-2034)
7.4 Europe Oligonucleotide Therapy Market Size by Country
7.4.1 Europe Oligonucleotide Therapy Market Size by Country: 2018 VS 2022 VS 2034
7.4.2 Europe Oligonucleotide Therapy Market Size by Country (2018-2024)
7.4.3 Europe Oligonucleotide Therapy Market Size by Country (2024-2034)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Oligonucleotide Therapy Market Size (2018-2034)
8.2 China Oligonucleotide Therapy Market Size by Type
8.2.1 China Oligonucleotide Therapy Market Size by Type (2018-2024)
8.2.2 China Oligonucleotide Therapy Market Size by Type (2024-2034)
8.2.3 China Oligonucleotide Therapy Market Share by Type (2018-2034)
8.3 China Oligonucleotide Therapy Market Size by Application
8.3.1 China Oligonucleotide Therapy Market Size by Application (2018-2024)
8.3.2 China Oligonucleotide Therapy Market Size by Application (2024-2034)
8.3.3 China Oligonucleotide Therapy Market Share by Application (2018-2034)
9 Asia (excluding China)
9.1 Asia Oligonucleotide Therapy Market Size (2018-2034)
9.2 Asia Oligonucleotide Therapy Market Size by Type
9.2.1 Asia Oligonucleotide Therapy Market Size by Type (2018-2024)
9.2.2 Asia Oligonucleotide Therapy Market Size by Type (2024-2034)
9.2.3 Asia Oligonucleotide Therapy Market Share by Type (2018-2034)
9.3 Asia Oligonucleotide Therapy Market Size by Application
9.3.1 Asia Oligonucleotide Therapy Market Size by Application (2018-2024)
9.3.2 Asia Oligonucleotide Therapy Market Size by Application (2024-2034)
9.3.3 Asia Oligonucleotide Therapy Market Share by Application (2018-2034)
9.4 Asia Oligonucleotide Therapy Market Size by Region
9.4.1 Asia Oligonucleotide Therapy Market Size by Region: 2018 VS 2022 VS 2034
9.4.2 Asia Oligonucleotide Therapy Market Size by Region (2018-2024)
9.4.3 Asia Oligonucleotide Therapy Market Size by Region (2024-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Oligonucleotide Therapy Market Size (2018-2034)
10.2 Middle East, Africa, and Latin America Oligonucleotide Therapy Market Size by Type
10.2.1 Middle East, Africa, and Latin America Oligonucleotide Therapy Market Size by Type (2018-2024)
10.2.2 Middle East, Africa, and Latin America Oligonucleotide Therapy Market Size by Type (2024-2034)
10.2.3 Middle East, Africa, and Latin America Oligonucleotide Therapy Market Share by Type (2018-2034)
10.3 Middle East, Africa, and Latin America Oligonucleotide Therapy Market Size by Application
10.3.1 Middle East, Africa, and Latin America Oligonucleotide Therapy Market Size by Application (2018-2024)
10.3.2 Middle East, Africa, and Latin America Oligonucleotide Therapy Market Size by Application (2024-2034)
10.3.3 Middle East, Africa, and Latin America Oligonucleotide Therapy Market Share by Application (2018-2034)
10.4 Middle East, Africa, and Latin America Oligonucleotide Therapy Market Size by Country
10.4.1 Middle East, Africa, and Latin America Oligonucleotide Therapy Market Size by Country: 2018 VS 2022 VS 2034
10.4.2 Middle East, Africa, and Latin America Oligonucleotide Therapy Market Size by Country (2018-2024)
10.4.3 Middle East, Africa, and Latin America Oligonucleotide Therapy Market Size by Country (2024-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Alnylam Pharmaceuticals Inc.
11.1.1 Alnylam Pharmaceuticals Inc. Company Details
11.1.2 Alnylam Pharmaceuticals Inc. Business Overview
11.1.3 Alnylam Pharmaceuticals Inc. Oligonucleotide Therapy Introduction
11.1.4 Alnylam Pharmaceuticals Inc. Revenue in Oligonucleotide Therapy Business (2018-2024)
11.1.5 Alnylam Pharmaceuticals Inc. Recent Developments
11.2 Biogen
11.2.1 Biogen Company Details
11.2.2 Biogen Business Overview
11.2.3 Biogen Oligonucleotide Therapy Introduction
11.2.4 Biogen Revenue in Oligonucleotide Therapy Business (2018-2024)
11.2.5 Biogen Recent Developments
11.3 Dynavax Technologies Corp.
11.3.1 Dynavax Technologies Corp. Company Details
11.3.2 Dynavax Technologies Corp. Business Overview
11.3.3 Dynavax Technologies Corp. Oligonucleotide Therapy Introduction
11.3.4 Dynavax Technologies Corp. Revenue in Oligonucleotide Therapy Business (2018-2024)
11.3.5 Dynavax Technologies Corp. Recent Developments
11.4 Merck and Co.
11.4.1 Merck and Co. Company Details
11.4.2 Merck and Co. Business Overview
11.4.3 Merck and Co. Oligonucleotide Therapy Introduction
11.4.4 Merck and Co. Revenue in Oligonucleotide Therapy Business (2018-2024)
11.4.5 Merck and Co. Recent Developments
11.5 Miragen Therapeuutics Inc.
11.5.1 Miragen Therapeuutics Inc. Company Details
11.5.2 Miragen Therapeuutics Inc. Business Overview
11.5.3 Miragen Therapeuutics Inc. Oligonucleotide Therapy Introduction
11.5.4 Miragen Therapeuutics Inc. Revenue in Oligonucleotide Therapy Business (2018-2024)
11.5.5 Miragen Therapeuutics Inc. Recent Developments
11.6 Sarepta Therapeutics Inc.
11.6.1 Sarepta Therapeutics Inc. Company Details
11.6.2 Sarepta Therapeutics Inc. Business Overview
11.6.3 Sarepta Therapeutics Inc. Oligonucleotide Therapy Introduction
11.6.4 Sarepta Therapeutics Inc. Revenue in Oligonucleotide Therapy Business (2018-2024)
11.6.5 Sarepta Therapeutics Inc. Recent Developments
11.7 GlaxoSmithKline
11.7.1 GlaxoSmithKline Company Details
11.7.2 GlaxoSmithKline Business Overview
11.7.3 GlaxoSmithKline Oligonucleotide Therapy Introduction
11.7.4 GlaxoSmithKline Revenue in Oligonucleotide Therapy Business (2018-2024)
11.7.5 GlaxoSmithKline Recent Developments
11.8 Pfizer
11.8.1 Pfizer Company Details
11.8.2 Pfizer Business Overview
11.8.3 Pfizer Oligonucleotide Therapy Introduction
11.8.4 Pfizer Revenue in Oligonucleotide Therapy Business (2018-2024)
11.8.5 Pfizer Recent Developments
11.9 Gilead Sciences
11.9.1 Gilead Sciences Company Details
11.9.2 Gilead Sciences Business Overview
11.9.3 Gilead Sciences Oligonucleotide Therapy Introduction
11.9.4 Gilead Sciences Revenue in Oligonucleotide Therapy Business (2018-2024)
11.9.5 Gilead Sciences Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Oligonucleotide Therapy Market Size Growth Rate by Type (US$ Million), 2018 VS 2022 VS 2034
Table 2. Key Players of Antisense Oligonucleotide
Table 3. Key Players of Aptamer
Table 4. Key Players of Others
Table 5. Global Oligonucleotide Therapy Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2034
Table 6. Global Oligonucleotide Therapy Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2034
Table 7. Global Oligonucleotide Therapy Market Size by Region (2018-2024) & (US$ Million)
Table 8. Global Oligonucleotide Therapy Market Share by Region (2018-2024)
Table 9. Global Oligonucleotide Therapy Forecasted Market Size by Region (2024-2034) & (US$ Million)
Table 10. Global Oligonucleotide Therapy Market Share by Region (2024-2034)
Table 11. Oligonucleotide Therapy Market Trends
Table 12. Oligonucleotide Therapy Market Drivers
Table 13. Oligonucleotide Therapy Market Challenges
Table 14. Oligonucleotide Therapy Market Restraints
Table 15. Global Oligonucleotide Therapy Revenue by Players (2018-2024) & (US$ Million)
Table 16. Global Oligonucleotide Therapy Revenue Share by Players (2018-2024)
Table 17. Global Top Oligonucleotide Therapy by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oligonucleotide Therapy as of 2022)
Table 18. Global Oligonucleotide Therapy Industry Ranking 2021 VS 2022 VS 2024
Table 19. Global 5 Largest Players Market Share by Oligonucleotide Therapy Revenue (CR5 and HHI) & (2018-2024)
Table 20. Global Key Players of Oligonucleotide Therapy, Headquarters and Area Served
Table 21. Global Key Players of Oligonucleotide Therapy, Product and Application
Table 22. Global Key Players of Oligonucleotide Therapy, Product and Application
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Oligonucleotide Therapy Market Size by Type (2018-2024) & (US$ Million)
Table 25. Global Oligonucleotide Therapy Revenue Market Share by Type (2018-2024)
Table 26. Global Oligonucleotide Therapy Forecasted Market Size by Type (2024-2034) & (US$ Million)
Table 27. Global Oligonucleotide Therapy Revenue Market Share by Type (2024-2034)
Table 28. Global Oligonucleotide Therapy Market Size by Application (2018-2024) & (US$ Million)
Table 29. Global Oligonucleotide Therapy Revenue Share by Application (2018-2024)
Table 30. Global Oligonucleotide Therapy Forecasted Market Size by Application (2024-2034) & (US$ Million)
Table 31. Global Oligonucleotide Therapy Revenue Share by Application (2024-2034)
Table 32. North America Oligonucleotide Therapy Market Size by Type (2018-2024) & (US$ Million)
Table 33. North America Oligonucleotide Therapy Market Size by Type (2024-2034) & (US$ Million)
Table 34. North America Oligonucleotide Therapy Market Size by Application (2018-2024) & (US$ Million)
Table 35. North America Oligonucleotide Therapy Market Size by Application (2024-2034) & (US$ Million)
Table 36. North America Oligonucleotide Therapy Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 37. North America Oligonucleotide Therapy Market Size by Country (2018-2024) & (US$ Million)
Table 38. North America Oligonucleotide Therapy Market Size by Country (2024-2034) & (US$ Million)
Table 39. Europe Oligonucleotide Therapy Market Size by Type (2018-2024) & (US$ Million)
Table 40. Europe Oligonucleotide Therapy Market Size by Type (2024-2034) & (US$ Million)
Table 41. Europe Oligonucleotide Therapy Market Size by Application (2018-2024) & (US$ Million)
Table 42. Europe Oligonucleotide Therapy Market Size by Application (2024-2034) & (US$ Million)
Table 43. Europe Oligonucleotide Therapy Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 44. Europe Oligonucleotide Therapy Market Size by Country (2018-2024) & (US$ Million)
Table 45. Europe Oligonucleotide Therapy Market Size by Country (2024-2034) & (US$ Million)
Table 46. China Oligonucleotide Therapy Market Size by Type (2018-2024) & (US$ Million)
Table 47. China Oligonucleotide Therapy Market Size by Type (2024-2034) & (US$ Million)
Table 48. China Oligonucleotide Therapy Market Size by Application (2018-2024) & (US$ Million)
Table 49. China Oligonucleotide Therapy Market Size by Application (2024-2034) & (US$ Million)
Table 50. Asia Oligonucleotide Therapy Market Size by Type (2018-2024) & (US$ Million)
Table 51. Asia Oligonucleotide Therapy Market Size by Type (2024-2034) & (US$ Million)
Table 52. Asia Oligonucleotide Therapy Market Size by Application (2018-2024) & (US$ Million)
Table 53. Asia Oligonucleotide Therapy Market Size by Application (2024-2034) & (US$ Million)
Table 54. Asia Oligonucleotide Therapy Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2034
Table 55. Asia Oligonucleotide Therapy Market Size by Region (2018-2024) & (US$ Million)
Table 56. Asia Oligonucleotide Therapy Market Size by Region (2024-2034) & (US$ Million)
Table 57. Middle East, Africa, and Latin America Oligonucleotide Therapy Market Size by Type (2018-2024) & (US$ Million)
Table 58. Middle East, Africa, and Latin America Oligonucleotide Therapy Market Size by Type (2024-2034) & (US$ Million)
Table 59. Middle East, Africa, and Latin America Oligonucleotide Therapy Market Size by Application (2018-2024) & (US$ Million)
Table 60. Middle East, Africa, and Latin America Oligonucleotide Therapy Market Size by Application (2024-2034) & (US$ Million)
Table 61. Middle East, Africa, and Latin America Oligonucleotide Therapy Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 62. Middle East, Africa, and Latin America Oligonucleotide Therapy Market Size by Country (2018-2024) & (US$ Million)
Table 63. Middle East, Africa, and Latin America Oligonucleotide Therapy Market Size by Country (2024-2034) & (US$ Million)
Table 64. Alnylam Pharmaceuticals Inc. Company Details
Table 65. Alnylam Pharmaceuticals Inc. Business Overview
Table 66. Alnylam Pharmaceuticals Inc. Oligonucleotide Therapy Product
Table 67. Alnylam Pharmaceuticals Inc. Revenue in Oligonucleotide Therapy Business (2018-2024) & (US$ Million)
Table 68. Alnylam Pharmaceuticals Inc. Recent Developments
Table 69. Biogen Company Details
Table 70. Biogen Business Overview
Table 71. Biogen Oligonucleotide Therapy Product
Table 72. Biogen Revenue in Oligonucleotide Therapy Business (2018-2024) & (US$ Million)
Table 73. Biogen Recent Developments
Table 74. Dynavax Technologies Corp. Company Details
Table 75. Dynavax Technologies Corp. Business Overview
Table 76. Dynavax Technologies Corp. Oligonucleotide Therapy Product
Table 77. Dynavax Technologies Corp. Revenue in Oligonucleotide Therapy Business (2018-2024) & (US$ Million)
Table 78. Dynavax Technologies Corp. Recent Developments
Table 79. Merck and Co. Company Details
Table 80. Merck and Co. Business Overview
Table 81. Merck and Co. Oligonucleotide Therapy Product
Table 82. Merck and Co. Revenue in Oligonucleotide Therapy Business (2018-2024) & (US$ Million)
Table 83. Merck and Co. Recent Developments
Table 84. Miragen Therapeuutics Inc. Company Details
Table 85. Miragen Therapeuutics Inc. Business Overview
Table 86. Miragen Therapeuutics Inc. Oligonucleotide Therapy Product
Table 87. Miragen Therapeuutics Inc. Revenue in Oligonucleotide Therapy Business (2018-2024) & (US$ Million)
Table 88. Miragen Therapeuutics Inc. Recent Developments
Table 89. Sarepta Therapeutics Inc. Company Details
Table 90. Sarepta Therapeutics Inc. Business Overview
Table 91. Sarepta Therapeutics Inc. Oligonucleotide Therapy Product
Table 92. Sarepta Therapeutics Inc. Revenue in Oligonucleotide Therapy Business (2018-2024) & (US$ Million)
Table 93. Sarepta Therapeutics Inc. Recent Developments
Table 94. GlaxoSmithKline Company Details
Table 95. GlaxoSmithKline Business Overview
Table 96. GlaxoSmithKline Oligonucleotide Therapy Product
Table 97. GlaxoSmithKline Revenue in Oligonucleotide Therapy Business (2018-2024) & (US$ Million)
Table 98. GlaxoSmithKline Recent Developments
Table 99. Pfizer Company Details
Table 100. Pfizer Business Overview
Table 101. Pfizer Oligonucleotide Therapy Product
Table 102. Pfizer Revenue in Oligonucleotide Therapy Business (2018-2024) & (US$ Million)
Table 103. Pfizer Recent Developments
Table 104. Gilead Sciences Company Details
Table 105. Gilead Sciences Business Overview
Table 106. Gilead Sciences Oligonucleotide Therapy Product
Table 107. Gilead Sciences Revenue in Oligonucleotide Therapy Business (2018-2024) & (US$ Million)
Table 108. Gilead Sciences Recent Developments
Table 109. Research Programs/Design for This Report
Table 110. Key Data Information from Secondary Sources
Table 111. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Oligonucleotide Therapy Market Size Growth Rate by Type, 2018 VS 2022 VS 2034 (US$ Million)
Figure 2. Global Oligonucleotide Therapy Market Share by Type: 2022 VS 2034
Figure 3. Antisense Oligonucleotide Features
Figure 4. Aptamer Features
Figure 5. Others Features
Figure 6. Global Oligonucleotide Therapy Market Size Growth Rate by Application, 2018 VS 2022 VS 2034 (US$ Million)
Figure 7. Global Oligonucleotide Therapy Market Share by Application: 2022 VS 2034
Figure 8. Infectious Diseases Case Studies
Figure 9. Oncology Case Studies
Figure 10. Neurodegenerative Disorders Case Studies
Figure 11. Cardiovascular Diseases Case Studies
Figure 12. Kidney Diseases Case Studies
Figure 13. Others Case Studies
Figure 14. Oligonucleotide Therapy Report Years Considered
Figure 15. Global Oligonucleotide Therapy Market Size (US$ Million), Year-over-Year: 2018-2034
Figure 16. Global Oligonucleotide Therapy Market Size, (US$ Million), 2018 VS 2022 VS 2034
Figure 17. Global Oligonucleotide Therapy Market Share by Region: 2022 VS 2034
Figure 18. Global Oligonucleotide Therapy Market Share by Players in 2022
Figure 19. Global Top Oligonucleotide Therapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oligonucleotide Therapy as of 2022)
Figure 20. The Top 10 and 5 Players Market Share by Oligonucleotide Therapy Revenue in 2022
Figure 21. North America Oligonucleotide Therapy Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 22. North America Oligonucleotide Therapy Market Share by Type (2018-2034)
Figure 23. North America Oligonucleotide Therapy Market Share by Application (2018-2034)
Figure 24. North America Oligonucleotide Therapy Market Share by Country (2018-2034)
Figure 25. United States Oligonucleotide Therapy Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 26. Canada Oligonucleotide Therapy Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 27. Europe Oligonucleotide Therapy Market Size YoY (2018-2034) & (US$ Million)
Figure 28. Europe Oligonucleotide Therapy Market Share by Type (2018-2034)
Figure 29. Europe Oligonucleotide Therapy Market Share by Application (2018-2034)
Figure 30. Europe Oligonucleotide Therapy Market Share by Country (2018-2034)
Figure 31. Germany Oligonucleotide Therapy Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 32. France Oligonucleotide Therapy Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 33. U.K. Oligonucleotide Therapy Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 34. Italy Oligonucleotide Therapy Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 35. Russia Oligonucleotide Therapy Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 36. Nordic Countries Oligonucleotide Therapy Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 37. China Oligonucleotide Therapy Market Size YoY (2018-2034) & (US$ Million)
Figure 38. China Oligonucleotide Therapy Market Share by Type (2018-2034)
Figure 39. China Oligonucleotide Therapy Market Share by Application (2018-2034)
Figure 40. Asia Oligonucleotide Therapy Market Size YoY (2018-2034) & (US$ Million)
Figure 41. Asia Oligonucleotide Therapy Market Share by Type (2018-2034)
Figure 42. Asia Oligonucleotide Therapy Market Share by Application (2018-2034)
Figure 43. Asia Oligonucleotide Therapy Market Share by Region (2018-2034)
Figure 44. Japan Oligonucleotide Therapy Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 45. South Korea Oligonucleotide Therapy Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 46. China Taiwan Oligonucleotide Therapy Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 47. Southeast Asia Oligonucleotide Therapy Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 48. India Oligonucleotide Therapy Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 49. Australia Oligonucleotide Therapy Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 50. Middle East, Africa, and Latin America Oligonucleotide Therapy Market Size YoY (2018-2034) & (US$ Million)
Figure 51. Middle East, Africa, and Latin America Oligonucleotide Therapy Market Share by Type (2018-2034)
Figure 52. Middle East, Africa, and Latin America Oligonucleotide Therapy Market Share by Application (2018-2034)
Figure 53. Middle East, Africa, and Latin America Oligonucleotide Therapy Market Share by Country (2018-2034)
Figure 54. Brazil Oligonucleotide Therapy Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 55. Mexico Oligonucleotide Therapy Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 56. Turkey Oligonucleotide Therapy Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 57. Saudi Arabia Oligonucleotide Therapy Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 58. Israel Oligonucleotide Therapy Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 59. GCC Countries Oligonucleotide Therapy Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 60. Alnylam Pharmaceuticals Inc. Revenue Growth Rate in Oligonucleotide Therapy Business (2018-2024)
Figure 61. Biogen Revenue Growth Rate in Oligonucleotide Therapy Business (2018-2024)
Figure 62. Dynavax Technologies Corp. Revenue Growth Rate in Oligonucleotide Therapy Business (2018-2024)
Figure 63. Merck and Co. Revenue Growth Rate in Oligonucleotide Therapy Business (2018-2024)
Figure 64. Miragen Therapeuutics Inc. Revenue Growth Rate in Oligonucleotide Therapy Business (2018-2024)
Figure 65. Sarepta Therapeutics Inc. Revenue Growth Rate in Oligonucleotide Therapy Business (2018-2024)
Figure 66. GlaxoSmithKline Revenue Growth Rate in Oligonucleotide Therapy Business (2018-2024)
Figure 67. Pfizer Revenue Growth Rate in Oligonucleotide Therapy Business (2018-2024)
Figure 68. Gilead Sciences Revenue Growth Rate in Oligonucleotide Therapy Business (2018-2024)
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries